Loncar Cancer Immunotherapy Etf Probability Of Bankruptcy
| CNCR Etf | USD 10.07 0.43 4.10% |
Loncar |
Loncar Cancer Immunotherapy ETF probability of distress Analysis
Loncar Cancer's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Loncar Cancer Probability Of Bankruptcy | Less than 10% |
Most of Loncar Cancer's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Loncar Cancer Immunotherapy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Loncar Cancer probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Loncar Cancer odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Loncar Cancer Immunotherapy financial health.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Loncar Cancer Immunotherapy has a Probability Of Bankruptcy of 10.0%. This is much higher than that of the Loncar Investments family and significantly higher than that of the Health category. The probability of bankruptcy for all United States etfs is notably lower than that of the firm.
Loncar Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Loncar Cancer's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Loncar Cancer could also be used in its relative valuation, which is a method of valuing Loncar Cancer by comparing valuation metrics of similar companies.Loncar Cancer is currently under evaluation in probability of bankruptcy as compared to similar ETFs.
Loncar Fundamentals
| Price To Earning | 24.63 X | |||
| Price To Book | 1.99 X | |||
| Price To Sales | 1.24 X | |||
| Number Of Employees | 395 | |||
| Beta | 0.92 | |||
| Total Asset | 20.52 M | |||
| One Year Return | (32.60) % | |||
| Three Year Return | (15.80) % | |||
| Five Year Return | (9.00) % | |||
| Net Asset | 20.52 M | |||
| Last Dividend Paid | 0.35 | |||
| Equity Positions Weight | 99.87 % |
About Loncar Cancer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Loncar Cancer Immunotherapy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Loncar Cancer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Loncar Cancer Immunotherapy based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Loncar Cancer Immuno is a strong investment it is important to analyze Loncar Cancer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Loncar Cancer's future performance. For an informed investment choice regarding Loncar Etf, refer to the following important reports: Check out Loncar Cancer Piotroski F Score and Loncar Cancer Altman Z Score analysis. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.